替唑胺对比利奈唑胺治疗革兰阳性呼吸机相关肺炎的3期随机双盲研究
这项全球3期随机双盲非劣效试验纳入726例革兰阳性通气HABP/VABP患者,比较替唑胺磷酸盐与利奈唑胺。替唑胺在第28天全因死亡率上非劣于利奈唑胺,但研究者评估的治愈试验临床应答未达非劣效,两药耐受性均良好。
要点
- 第28天全因死亡率替唑胺非劣于利奈唑胺(28.1% vs 26.4%)。
- 治愈试验研究者评估临床应答未达非劣效(56.3% vs 63.9%)。
- 两药药物相关不良事件发生率分别为8.1%和11.9%。
核心结论
- 替唑胺在革兰阳性通气HABP/VABP治疗中第28天全因死亡率非劣于利奈唑胺。
- 研究者评估的治愈试验临床应答未证明替唑胺非劣效。
- 两药均耐受良好。
研究设计与样本
- 全球、随机、非劣效、双盲、双模拟3期试验,患者按1:1随机分组。
- 替唑胺磷酸盐静脉200 mg每日一次用7天;利奈唑胺静脉600 mg每12小时一次用10天;合并革兰阳性菌血症者疗程14天。
- 共随机726例(替唑胺366例,利奈唑胺360例),主要疗效终点在意向治疗人群中分析。
主要发现
- 第28天全因死亡率:替唑胺28.1% vs 利奈唑胺26.4%,差值-1.8%(95%CI:-8.2至4.7)。
- 治愈试验研究者评估临床治愈率:替唑胺56.3% vs 利奈唑胺63.9%,差值-7.6%(97.5%CI:-15.7至0.5)。
- 事后分析未发现单一因素可解释两组临床应答差异。
- 药物相关不良事件:替唑胺8.1%,利奈唑胺11.9%。
- 基线耐甲氧西林金黄色葡萄球菌总体发生率为31.3%。
关键数值与推荐
- 第28天全因死亡率非劣效界值为10%。
- 治愈试验研究者评估临床应答非劣效界值为12.5%。
临床怎么用
- 对于革兰阳性通气HABP/VABP,替唑胺可作为兼顾28天死亡率的治疗选择。
- 临床应答未达非劣效,选择替唑胺时需权衡疗效与安全性。
局限性
- 原文摘要未报告其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP) are associated with high mortality rates. We evaluated the efficacy and safety of tedizolid (administered as tedizolid phosphate) for treatment of gram-positive ventilated HABP/VABP. METHODS: In this randomized, noninferiority, double-blind, double-dummy, global phase 3 trial, patients were randomized 1:1 to receive intravenous tedizolid phosphate 200 mg once daily for 7 days or intravenous linezolid 600 mg every 12 hours for 10 days. Treatment was 14 days in patients with concurrent gram-positive bacteremia. The primary efficacy end points were day 28 all-cause mortality (ACM; noninferiority margin, 10%) and investigator-assessed clinical response at test of cure (TOC; noninferiority margin, 12.5%) in the intention-to-treat population. RESULTS: Overall, 726 patients were randomized (tedizolid, n = 366; linezolid, n = 360). Baseline characteristics, including incidence of methicillin-resistant Staphylococcus aureus (31.3% overall), were well balanced. Tedizolid was noninferior to linezolid for day 28 ACM rate: 28.1% and 26.4%, respectively (difference, -1.8%; 95% confidence interval [CI]: -8.2 to 4.7). Noninferiority of tedizolid was not demonstrated for investigator-assessed clinical cure at TOC (tedizolid, 56.3% vs linezolid, 63.9%; difference, -7.6%; 97.5% CI: -15.7 to 0.5). In post hoc analyses, no single factor accounted for the difference in clinical response between treatment groups. Drug-related adverse events occurred in 8.1% and 11.9% of patients who received tedizolid and linezolid, respectively. CONCLUSIONS: Tedizolid was noninferior to linezolid for day 28 ACM in the treatment of gram-positive ventilated HABP/VABP. Noninferiority of tedizolid for investigator-assessed clinical response at TOC was not demonstrated. Both drugs were well tolerated. CLINICAL TRIALS REGISTRATION: NCT02019420.
引用
- Wunderink RG, Roquilly A, Croce M, et al. A Phase 3, Randomized, Double-Blind Study Comparing Tedizolid Phosphate and Linezolid for Treatment of Ventilated Gram-Positive Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia. Clin Infect Dis. 2021. PMID: 33720350. doi:10.1093/cid/ciab032
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。